200 related articles for article (PubMed ID: 22328573)
1. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
2. The Novel Phosphodiesterase 9A Inhibitor BI 409306 Increases Cyclic Guanosine Monophosphate Levels in the Brain, Promotes Synaptic Plasticity, and Enhances Memory Function in Rodents.
Rosenbrock H; Giovannini R; Schänzle G; Koros E; Runge F; Fuchs H; Marti A; Reymann KG; Schröder UH; Fedele E; Dorner-Ciossek C
J Pharmacol Exp Ther; 2019 Dec; 371(3):633-641. PubMed ID: 31578258
[No Abstract] [Full Text] [Related]
3. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
4. High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.
Almeida CB; Traina F; Lanaro C; Canalli AA; Saad ST; Costa FF; Conran N
Br J Haematol; 2008 Sep; 142(5):836-44. PubMed ID: 18564357
[TBL] [Abstract][Full Text] [Related]
5. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
[TBL] [Abstract][Full Text] [Related]
6. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
7. Cyclic GMP metabolism and its role in brain physiology.
Domek-Łopacińska K; Strosznajder JB
J Physiol Pharmacol; 2005 Mar; 56 Suppl 2():15-34. PubMed ID: 16077188
[TBL] [Abstract][Full Text] [Related]
8. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution and subcellular localization of PDE9A variants.
Wang P; Wu P; Egan RW; Billah MM
Gene; 2003 Sep; 314():15-27. PubMed ID: 14527714
[TBL] [Abstract][Full Text] [Related]
10. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Lee DI; Zhu G; Sasaki T; Cho GS; Hamdani N; Holewinski R; Jo SH; Danner T; Zhang M; Rainer PP; Bedja D; Kirk JA; Ranek MJ; Dostmann WR; Kwon C; Margulies KB; Van Eyk JE; Paulus WJ; Takimoto E; Kass DA
Nature; 2015 Mar; 519(7544):472-6. PubMed ID: 25799991
[TBL] [Abstract][Full Text] [Related]
12. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition.
Kroker KS; Mathis C; Marti A; Cassel JC; Rosenbrock H; Dorner-Ciossek C
Neurobiol Aging; 2014 Sep; 35(9):2072-8. PubMed ID: 24746365
[TBL] [Abstract][Full Text] [Related]
13. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
[TBL] [Abstract][Full Text] [Related]
14. Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.
Johnson WB; Katugampola S; Able S; Napier C; Harding SE
Life Sci; 2012 Feb; 90(9-10):328-36. PubMed ID: 22261303
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterases in neurodegenerative disorders.
Bollen E; Prickaerts J
IUBMB Life; 2012 Dec; 64(12):965-70. PubMed ID: 23129425
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP.
Kroker KS; Rast G; Giovannini R; Marti A; Dorner-Ciossek C; Rosenbrock H
Neuropharmacology; 2012 Apr; 62(5-6):1964-74. PubMed ID: 22245562
[TBL] [Abstract][Full Text] [Related]
17. Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain.
Andreeva SG; Dikkes P; Epstein PM; Rosenberg PA
J Neurosci; 2001 Nov; 21(22):9068-76. PubMed ID: 11698617
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Singh N; Patra S
Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.
Boess FG; Hendrix M; van der Staay FJ; Erb C; Schreiber R; van Staveren W; de Vente J; Prickaerts J; Blokland A; Koenig G
Neuropharmacology; 2004 Dec; 47(7):1081-92. PubMed ID: 15555642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
